Simulations Plus Expands Marketing & Sales Operations in South America Through Partnership with the Institute of Pharmaceutic...
January 26 2021 - 8:30AM
Business Wire
New distribution channel will accelerate
adoption of software and services in emerging markets
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemical, and consumer goods industries, today
announced that it has entered into a distribution agreement with
the Institute of Pharmaceutical Sciences (ICF) to provide
marketing, sales, and technical support to organizations within
South America.
Founded in 2002, ICF is one of the largest pharmaceutical
research centers in Latin America and the first commercial
Brazilian laboratory to be fully certified by the Brazilian Health
Regulatory Agency (ANVISA) to conduct bioavailability and
bioequivalence trials. In addition to running clinical trials, ICF
has expertise developing complex formulation products such as
patches, nasal sprays, and inhalers for organizations globally.
With a staff of over 200 highly qualified scientists, ICF will
provide extensive connections throughout industry, academia, and
regulatory agencies to increase awareness of GastroPlus®, ADMET
Predictor®, and related services from Simulations Plus.
“Even though South America has emerged as a global manufacturing
hub, with expanded research facilities for pharmaceutical and
generic drug companies, the use of model-informed drug development
(MIDD) is in its infancy,” said Dr. Leonardo de Souza Teixeira, CEO
of ICF. “We are very happy forming this partnership with
Simulations Plus to spread the knowledge and application of MIDD to
support regulatory interactions.”
“Latin America is one of the fastest growing generic drug
markets in the world and expected to reach $48 billion in size by
2025,” added John DiBella, Simulations Plus division president. “To
capitalize on this opportunity, especially in the areas of
specialty products and non-oral drug delivery systems, we are
excited to be partnering with ICF, an established contract research
organization (CRO) leader with strong relationships throughout
Brazil and neighboring countries. We expect ICF’s expertise
administering laboratory testing and clinical studies to complement
our offerings to companies throughout the continent and, as a
bonus, provide Simulations Plus with new research opportunities to
continue advancing modeling and simulation science.”
About Simulations Plus, Inc. Simulations Plus, Inc. is a
leading provider of modeling and simulation software and consulting
services supporting drug discovery, development research, and
regulatory submissions. With our subsidiaries, Cognigen, DILIsym
Services, and Lixoft, we offer solutions which bridge machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, chemical, consumer goods companies
and regulatory agencies worldwide. For more information, visit our
website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn | YouTube
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126005222/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 slp@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024